Liquidia Corporation
LQDA
주식 순위
#4829
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
주가
$34.35
마지막 동기화: 2026-10-16
시가총액
$3.07B
변동 (1일)
-1.23%
변동 (1년)
52.81%
국가
US
거래 Liquidia Corporation (LQDA)
카테고리
Healthcare
Liquidia Corporation (LQDA)의 EPS
June 2026 기준 EPS TTM: $1.57
Liquidia Corporation의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $1.57입니다. 2023년 말에는 회사의 EPS가 $-1.21였으며, 이는 2022년의 EPS $-0.67와 증가입니다.
Liquidia Corporation의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.80% |
HK
|
